Sumitomo Mitsui Trust Group’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
Other funds holding BEAM
Sumitomo Mitsui Trust Group's BEAM Position: Q3 2026 in Review
Sumitomo Mitsui Trust Group reduced its Beam Therapeutics (BEAM) stake by 3.1% in Q3 2026, selling an estimated $2.95M and leaving 3,349,244 shares worth $81.9M. The position accounts for 0.05% of the portfolio, ranked #329.
Sumitomo Mitsui Trust Group first reported a position in BEAM in Q4 2020 and has held it in 24 quarters since. The position peaked at $122M in Q4 2025. 52 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.
- Sumitomo Mitsui Trust Group held 3,349,244 shares of Beam Therapeutics worth $81.9M as of Q3 2026.
- Sumitomo Mitsui Trust Group sold 105,799 Beam Therapeutics shares in Q3 2026, an estimated $2.95M.
- Beam Therapeutics made up 0.05% of Sumitomo Mitsui Trust Group's portfolio in Q3 2026, its #329 holding.
- Sumitomo Mitsui Trust Group first reported a position in Beam Therapeutics in Q4 2020 and has held it in 24 quarters since.
- Sumitomo Mitsui Trust Group's Beam Therapeutics position peaked at $122M in Q4 2025.
- 52 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.
Based on Sumitomo Mitsui Trust Group's 13F filing for Q3 2026, filed 29 Oct 2026.